These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
628 related items for PubMed ID: 25745368
1. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study. van Dijkhuizen EH, Bulatović Ćalasan M, Pluijm SM, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM. Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368 [Abstract] [Full Text] [Related]
2. Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review. van Dijkhuizen EH, Wulffraat NM. Pediatr Rheumatol Online J; 2014; 12():51. PubMed ID: 25525416 [Abstract] [Full Text] [Related]
3. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Bulatovic M, Heijstek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de Jonge R. Ann Rheum Dis; 2012 Sep; 71(9):1484-9. PubMed ID: 22473625 [Abstract] [Full Text] [Related]
6. Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results. Höfel L, Eppler B, Storf M, Schnöbel-Müller E, Haas JP, Hügle B. Pediatr Rheumatol Online J; 2018 Feb 13; 16(1):11. PubMed ID: 29433504 [Abstract] [Full Text] [Related]
7. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Bulatović M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, Kamphuis S, Kuis W, Egberts TC, Sinnema G, Rademaker CM, Wulffraat NM. Arthritis Rheum; 2011 Jul 13; 63(7):2007-13. PubMed ID: 21437879 [Abstract] [Full Text] [Related]
9. Countermeasures against methotrexate intolerance in juvenile idiopathic arthritis instituted by parents show no effect. Scheuern A, Tyrrell PN, Haas JP, Hügle B. Rheumatology (Oxford); 2017 Jun 01; 56(6):901-906. PubMed ID: 28122960 [Abstract] [Full Text] [Related]
10. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis. Funk RS, Chan MA, Becker ML. Pharmacotherapy; 2017 Jun 01; 37(6):700-711. PubMed ID: 28475276 [Abstract] [Full Text] [Related]
11. Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis. Zajc Avramovič M, Dolžan V, Toplak N, Accetto M, Lusa L, Avčin T. J Rheumatol; 2017 Aug 01; 44(8):1216-1223. PubMed ID: 28572465 [Abstract] [Full Text] [Related]
12. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, Ten Cate R, Guchelaar HJ. Arthritis Rheum; 2009 Jan 15; 61(1):46-51. PubMed ID: 19116975 [Abstract] [Full Text] [Related]
13. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. de Rotte MC, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RH, Wulffraat NM, de Jonge R. J Rheumatol; 2012 Oct 15; 39(10):2032-40. PubMed ID: 22859359 [Abstract] [Full Text] [Related]
14. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis. Alcântara AC, Leite CA, Leite AC, Sidrim JJ, Silva FS, Rocha FA. J Rheumatol; 2014 Feb 15; 41(2):338-44. PubMed ID: 24334641 [Abstract] [Full Text] [Related]
15. SLCO1B1 variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritis. Roszkiewicz J, Michałek D, Ryk A, Swacha Z, Szmyd B, Smolewska E. Scand J Rheumatol; 2021 May 15; 50(3):213-217. PubMed ID: 33025831 [Abstract] [Full Text] [Related]
16. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis. Batu ED, Sönmez HE, Gülhan B, Arıcı ZS, Topaloğlu R, Bilginer Y. Turk J Pediatr; 2017 May 15; 59(1):6-12. PubMed ID: 29168357 [Abstract] [Full Text] [Related]
17. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. Bava C, Mongelli F, Pistorio A, Bertamino M, Bracciolini G, Dalprà S, Davì S, Lanni S, Muratore V, Pederzoli S, Rosina S, Schiappapietra B, Suffia C, Varnier G, Verazza S, Giancane G, Consolaro A, Ravelli A. Pediatr Rheumatol Online J; 2019 Jul 25; 17(1):50. PubMed ID: 31345226 [Abstract] [Full Text] [Related]
18. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Bichler J, Benseler SM, Krumrey-Langkammerer M, Haas JP, Hügle B. Scand J Rheumatol; 2015 Jul 25; 44(4):280-3. PubMed ID: 25993023 [Abstract] [Full Text] [Related]
19. Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis. Kyvsgaard N, Mikkelsen TS, Als TD, Christensen AE, Corydon TJ, Herlin T. Pediatr Rheumatol Online J; 2021 Apr 01; 19(1):51. PubMed ID: 33794950 [Abstract] [Full Text] [Related]
20. Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis. Scheuern A, Fischer N, McDonald J, Brunner HI, Haas JP, Hügle B. Pediatr Rheumatol Online J; 2016 Feb 29; 14(1):11. PubMed ID: 26928923 [Abstract] [Full Text] [Related] Page: [Next] [New Search]